Results 1 to 10 of about 7,231 (113)

Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope

Acta Pharmaceutica Sinica B, 2022
The proteolysis targeting chimeras (PROTACs) technology has been rapidly developed since its birth in 2001, attracting rapidly growing attention of scientific institutes and pharmaceutical companies.
Zhengyu Jiang, Qidong You, Shicheng Xu
exaly   +3 more sources

Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents

Journal of Enzyme Inhibition and Medicinal Chemistry, 2022
Proteolytic targeting chimaeras (PROTACs) have been developed as an effective technology for targeted protein degradation. PROTACs are heterobifunctional molecules that can trigger the polyubiquitination of proteins of interest (POIs) by recruiting the ...
Dongming Xing, Lingyu Shi
exaly   +3 more sources

PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies

Molecules, 2023
A potential therapeutic strategy to treat conditions brought on by the aberrant production of a disease-causing protein is emerging for targeted protein breakdown using the PROTACs technology.
Anand Krishnan, Sumel Ashique
exaly   +3 more sources

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future

Molecules, 2022
The PROteolysis TArgeting Chimeras (PROTACs) is an innovative technique for the selective degradation of target proteins via the ubiquitin–proteasome system.
Jiao Li, Yuxin Gao
exaly   +3 more sources

Self-assembled PROTACs enable protein degradation to reprogram the tumor microenvironment for synergistically enhanced colorectal cancer immunotherapy

Bioactive Materials
Both β-catenin and STAT3 drive colorectal cancer (CRC) growth, progression, and immune evasion, and their co-overexpression is strongly associated with a poor prognosis.
Xin Luan, Shengxin Lu, Jiayi Lin
exaly   +3 more sources

Advantages of PROTACs in achieving selective degradation of homologous protein families [PDF]

Beilstein Journal of Organic Chemistry
Proteolysis-targeting chimeras (PROTACs) have emerged as a promising therapeutic modality and now represent an important addition to the toolkit of medicinal chemists.
Luxi Yang, Xinfei Mao, Jingyi Zhang, Jing Shu, Wenhai Huang, Xiaowu Dong, Yinqiao Chen, Mingfei Wu   +7 more
doaj   +2 more sources

Major Advances in Emerging Degrader Technologies

Frontiers in Cell and Developmental Biology, 2022
Recently, degrader technologies have attracted increasing interest in the academic field and the pharmaceuticals industry. As one of the degrader technologies, proteolysis-targeting chimeras (PROTACs) have emerged as an attractive pharmaceutical ...
Hang Luo, Li Wu, Li Wu, Yujian He, Chong Qin, Xinjing Tang   +5 more
doaj   +1 more source

PROTACs: The Future of Leukemia Therapeutics

Frontiers in Cell and Developmental Biology, 2022
The fight to find effective, long-lasting treatments for cancer has led many researchers to consider protein degrading entities. Recent developments in PROteolysis TArgeting Chimeras (PROTACs) have signified their potential as possible cancer therapies ...
Zubair Anwar, Muhammad Shahzad Ali, Antonio Galvano, Alessandro Perez, Maria La Mantia, Ihtisham Bukhari, Bartlomiej Swiatczak   +6 more
doaj   +1 more source

Glutathione‐Scavenging Nanoparticle‐Mediated PROTACs Delivery for Targeted Protein Degradation and Amplified Antitumor Effects

Advanced Science, 2023
PROteolysis TArgeting Chimeras (PROTACs) are an emerging class of promising therapeutic modalities that selectively degrade intracellular proteins of interest by hijacking the ubiquitin‐proteasome system.
Hai‐Jun Liu, Wei Chen, Gongwei Wu, Jun Zhou, Chuang Liu, Zhongmin Tang, Xiangang Huang, Jingjing Gao, Yufen Xiao, Na Kong, Nitin Joshi, Yihai Cao, Reza Abdi, Wei Tao   +13 more
doaj   +1 more source

PROTACs: Walking through hematological malignancies

Frontiers in Pharmacology, 2023
Proteolysis targeting chimeras (PROTACs) are heterobifunctional small molecules that uses the proteasome ubiquitin system to target proteins of interest and promote their degradation with remarkable selectivity.
Lara J. Bou Malhab, Habiba Alsafar, Habiba Alsafar, Saleh Ibrahim, Mohamed Rahmani, Mohamed Rahmani   +5 more
doaj   +1 more source